The price disclosure roadmap


The next batch of medicines to undergo price disclosure reductions has been revealed

The PBS has released the list of medicines that are to be included in the October 2020 cycle of price disclosure reductions.

Among the medicines included in this cycle are:

  • Ariprazole 10,15, 20 and 30mg tablets, to be reduced by 11.18% 
  • Bosentan 62.5 or 125mg tablets as monohydrate, to be reduced by 19.30%
  • Ezetimibe 10mg tablets, to experience a 27.62% price difference
  • Fenofibrate 125mg and 48mg tablets, with a 16.97% difference   
  • Olmesartan with hydrochlorothiazide oral tablets in three different formulations, to experience a price adjustment between 11% and 13%
  • Pregabalin 25, 75, 150 and 200mg, with a 23% price difference
  • Trasztuzumab injections in four formulations, to alter by 11.81%
  • Zoledronic Acid injections in three formulations, to reduce by 38%

Also included on the list are Rosuvastatin 10mg tablets (as calcium) and two Rituximab solutions for IV infusion. Each of these products were noted as having a pharmaceutical item/s that met the ‘no reduction’ criteria.

The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations), the PBS said.

Indicative prices for 1 October 2020 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by Mid – August.

Final prices for 1 October 2020 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from early September.

Go here to see the full list of October price disclosure changes.

Previous Supply shutdown
Next Research Roundup

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.